Their readlength is up to 100K, and accuracy 96% (from their early claims).
Bye bye pacbio, Ch 7 is coming. Just like old pal helicos.
Yes, don't forget the government shut down delayed caused issues with supply sales and Cap Eq orders, He seemed very positive on this point.
I don't get what you mean. HiSeq from ILMN is about 700K. PacBio RSII is about 750K. That doesn't explain why HiSeq outsell PacBio by 20 times. But there is a reason if you have seen the Pacbio RS. It is big as a mammoth and weighs a ton. No lab can have large enough space to have several RS. But on the throughput side, HiSeq is hundreds times higher than PacBio, with 99.9999% accuracy. The readlength is the only thing pacbio beats them by a lot. But their accuracy sucks.
If they are the best, they won't sell only 5 instruments in 3 months, and lower than last quarter, while HiSeq sold over 100 units. The only chance it will move up is news like Roche. I was happy the news finally came so I made a handsome profit. Other things about PacBio is all pipe dream, sorry it doesn't agree with your research but that is my view and may not be accurate.
PACB is the company with huge potential for big surprise in next quarter, and limited downside because sequencing business will grow moving forward in clinical and personalized genome space, and PACB is the best sequencing platform for clinical and personalized genome.
I do my home work and I buy incrementally because I can't trade with high speed traders.
I only buy undervalued stock and sell overvaluled stock. I suggest you do the same. PACB now is not a good buy, period.
nimuma......Haha...Read your own words and FIGURES, you're answering your own question.
Look, whoever is reading your posts here realize you want in PACB.......at a lower price.
They could possibly even beat their own sales projections.
Are you saying......sequentially they are NOT progressing ?
Don't be quite so obvious.
If it turns out so, I will congratulate you. But I will stay aside until real positive news or rumor comes out. I may miss a 30% jump, but loss is a lot harder to take from typical human psychology.
I agree sequestration and budget cut is an issue. But why ILMN peaked its sales for this quarter. and BGI just bought 37 Protons?
Despite a handful of sequencing tech enthusiasts, PacBio has very limited customer base. I think investors are misled by the scientific papers and fancy new discovery claimed by this small scientific community while the clinical market is still not touched by PacBio, not because of their marketing capability, but because their low raw accuracy.
Just to emphasize, PacBio read is only 85% accurate. Would you trust their sequencing data if your diagnostic is depending on a few base read accuracy? To achieve 99.99% accuracy to be clinically reliable, you need to sequence maybe 100 times, which will increase the cost much higher compared to ILMN or Life.
In the short term, if you bought the stock at 2 or 3, then sell and take the profit. It is nice profit! But if you bought over 5.5 or 6, then maybe hold. PacBio may have a chance to turn around, and its chance is much higher than half a year ago. But then you'll need patience.
I don't think PacBio mini will come out soon. I have seen their machine and HiSeq. PacBio RS has too complicated technology to be simplified as a mini-machine. And outsourcing their MFG will take a lot of capital and time. While the ILMN HiSeq is so simple and cheaply made. I can't tell you the difference between the cost of these two platforms.
Sequestration and budget cut are the reason for lower sale, I bet it will improve with Roche deal. Roche is shutting down, and for long read customer, PACB is the only option. PACB can sell lots of sequencers if they can reduce the sequencer price and increase consumable cost.
PACB should partner with Hitachi to make these sequencer at more cost cost effective.
More sequencer running means more revenue for PACB. Also, I bet they are working on PACB mini with Roche to target diagnostic market. Not sure when it will come out but it's set to come out...
This was taken from last quarter report:
"Going forward, Gong said the firm anticipates that its third-quarter revenue will grow sequentially and that the company expects to "at least double" its total instrument bookings over 2012, from 12."
They booked 4 new instrument in Q1, 7 in Q2, 5 in Q3. To at least double from 12, they need to book 8 instrument for Q4. Can they make it?
Will come back if dropped to lower $4 range.
Fact on Q3 reports.
New order down from 7 to 5 this Q
Burn rate the same (~20M)
Margin the same. (slightly less, ~17%).
Revenue slightly higher (~7M)
Roche deal was just a throwing in the tower deal. Still an anemic company.
Compared to ILMN, 10% jump, HiSeq new order historically high.
They could have realized some revenue from Roche's 35 million deal and beat the estimate, but they still look good and they might replace 454 sequencers with PACBIO sooner then you think.
Pacific Biosciences misses by $0.02, beats on revs (PACB) 5.25 -0.11 : Reports Q3 (Sep) loss of $0.31 per share, $0.02 worse than the Capital IQ Consensus Estimate of ($0.29); revenues rose 164.3% year/year to $7.4 mln vs the $7.08 mln consensus.
still stock has only one way to go and that is up till 7.5+